XML 15 R5.htm IDEA: XBRL DOCUMENT v3.20.2
CONSOLIDATED CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)
$ in Thousands
Total
Nano Tx Therapeutics [Member]
Series C Convertible Preferred Stock [Member]
Convertible Preferred Stock [Member]
Convertible Preferred Stock [Member]
Series B Convertible Preferred Stock [Member]
Convertible Preferred Stock [Member]
Series B and C Convertible Preferred Stock [Member]
Common Stock [Member]
Common Stock [Member]
Nano Tx Therapeutics [Member]
Common Stock [Member]
Series B Convertible Preferred Stock [Member]
Common Stock [Member]
Series B and C Convertible Preferred Stock [Member]
Additional Paid-in Capital [Member]
Additional Paid-in Capital [Member]
Nano Tx Therapeutics [Member]
Additional Paid-in Capital [Member]
Series C Convertible Preferred Stock [Member]
Accumulated Other Comprehensive Income [Member]
Accumulated Deficit [Member]
Balance at Dec. 31, 2018 $ 5,225                   $ 418,390     $ 1,218 $ (414,383)
Balance (in shares) at Dec. 31, 2018       4,606,000     296,609,000                
Share-based compensation 49                   49        
Sale of common stock, net 1,873                   1,873        
Sale of common stock, net (in shares)             139,855,000                
Conversion of Convertible Preferred Stock into common stock (share)         (66,000)       1,653,000            
Foreign currency translation adjustment and accumulated other comprehensive income (140)                         (140)  
Net income (loss) (3,150)                           (3,150)
Balance at Mar. 31, 2019 3,857                   420,312     1,078 (417,533)
Balance (in shares) at Mar. 31, 2019       4,540,000     438,117,000                
Balance at Dec. 31, 2018 5,225                   418,390     1,218 (414,383)
Balance (in shares) at Dec. 31, 2018       4,606,000     296,609,000                
Net income (loss) (11,771)                            
Balance at Sep. 30, 2019 160           $ 3       426,311       (426,154)
Balance (in shares) at Sep. 30, 2019       1,959,000     2,841,588,000                
Balance at Dec. 31, 2018 5,225                   418,390     1,218 (414,383)
Balance (in shares) at Dec. 31, 2018       4,606,000     296,609,000                
Balance at Dec. 31, 2019 $ 1,160           $ 4       426,426       (425,270)
Balance (in shares) at Dec. 31, 2019 3,880,588     1,959,000     3,880,588,000                
Balance at Mar. 31, 2019 $ 3,857                   420,312     1,078 (417,533)
Balance (in shares) at Mar. 31, 2019       4,540,000     438,117,000                
Share-based compensation 28                   28        
Sale of common stock, net 64                   64        
Sale of common stock, net (in shares)             5,000,000                
Foreign currency translation adjustment and accumulated other comprehensive income (1,078)                         $ (1,078)  
Net income (loss) (9,147)                           (9,147)
Balance at Jun. 30, 2019 (6,276)                   420,404       (426,680)
Balance (in shares) at Jun. 30, 2019       4,540,000     443,117,000                
Issuance of common stock for exercise of warrants 490                   490        
Issuance of common stock for exercise of warrants (in shares)             65,415,000                
Reclassification of warrant liabilities 794                   794        
Share-based compensation 29                   29        
Sale of common stock and pre-funded warrants, net of offering costs 4,597           $ 3       4,594        
Sale of common stock and pre-funded warrants, net of offering costs (in shares)             2,000,510,000                
Conversion of Convertible Preferred Stock into common stock (share)           (2,581,000)       332,546,000          
Exercise of warrants (in shares)             65,415,000                
Beneficial conversion feature related to Series C Convertible Preferred Stock     $ 554                   $ 554    
Accretion of beneficial conversion feature related to Series C Convertible Preferred Stock     $ (554)                   $ (554)    
Net income (loss) 526                           526
Balance at Sep. 30, 2019 160           $ 3       426,311       (426,154)
Balance (in shares) at Sep. 30, 2019       1,959,000     2,841,588,000                
Balance at Dec. 31, 2019 $ 1,160           $ 4       426,426       (425,270)
Balance (in shares) at Dec. 31, 2019 3,880,588     1,959,000     3,880,588,000                
Share-based compensation $ 12                   12        
Net income (loss) (1,087)                           (1,087)
Balance at Mar. 31, 2020 85           $ 4       426,438       (426,357)
Balance (in shares) at Mar. 31, 2020       1,959,000     3,880,588,000                
Balance at Dec. 31, 2019 $ 1,160           $ 4       426,426       (425,270)
Balance (in shares) at Dec. 31, 2019 3,880,588     1,959,000     3,880,588,000                
Net income (loss) $ (4,654)                            
Balance at Sep. 30, 2020 $ 2,621           $ 5       432,540       (429,924)
Balance (in shares) at Sep. 30, 2020 4,591,415     1,954,000     4,591,415,000                
Balance at Mar. 31, 2020 $ 85           $ 4       426,438       (426,357)
Balance (in shares) at Mar. 31, 2020       1,959,000     3,880,588,000                
Issuance of common stock for exercise of warrants 366                   366        
Issuance of common stock for exercise of warrants (in shares)             162,500,000                
Reclassification of warrant liabilities 4,264                   4,264        
Issuance of common stock for in process research and development acquired   $ 381                   $ 381      
Issuance of common stock for in process research and development acquired (in share)               230,769,000              
Share-based compensation 43                   43        
Exercise of warrants (in shares)             162,500,000                
Net income (loss) (1,839)                           (1,839)
Balance at Jun. 30, 2020 3,300           $ 4       431,492       (428,196)
Balance (in shares) at Jun. 30, 2020       1,959,000     4,273,857,000                
Issuance of common stock for exercise of warrants 715           $ 1       714        
Issuance of common stock for exercise of warrants (in shares)             317,521,000                
Reclassification of warrant liabilities 240                   240        
Share-based compensation 94                   94        
Conversion of Convertible Preferred Stock into common stock (share)         (5,000)       37,000            
Exercise of warrants (in shares)             317,521,000                
Net income (loss) (1,728)                           (1,728)
Balance at Sep. 30, 2020 $ 2,621           $ 5       $ 432,540       $ (429,924)
Balance (in shares) at Sep. 30, 2020 4,591,415     1,954,000     4,591,415,000